Blog
RSS FeedPosted by Michael Wonder on 03 Feb 2020
FDA and FTC announce new efforts to further deter anti-competitive business practices, support competitive market for biological products to help Americans
3 February 2020 - The U.S. Food and Drug Administration and the Federal Trade Commission today signed a joint statement regarding ...
Posted by Michael Wonder on 03 Feb 2020
Pfizer receives positive CHMP opinion for oncology biosimilar, Ruxience (rituximab)
31 January 2020 - Pfizer today announced that the CHMP of the EMA has adopted a positive opinion, recommending marketing ...
Posted by Michael Wonder on 01 Feb 2020
Biosimilar rituximab on the PBS - information for health professionals and patients
1 February 2020 - On 1 February 2020 changes were made to the PBS listings for the biosimilar rituximab brand Truxima. ...
Posted by Michael Wonder on 30 Jan 2020
CMS payment policy plays role in biosimilar uptake
30 January 2020 - How does CMS payment policy for Medicare, Medicaid, and 340B hospitals affect biosimilar uptake? A speaker ...
Posted by Michael Wonder on 21 Jan 2020
Achieving cost savings with biosimilars will require new strategies, authors say
20 January 2020 - Improving access to fairly priced, quality-assured generics and biosimilars is essential to realizing the potential public ...
Posted by Michael Wonder on 21 Jan 2020
The biosimilar solution to expensive cancer care
20 January 2020 - In a recent column in Evidence-Based Oncology, Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer ...
Posted by Michael Wonder on 02 Jan 2020
Biosimilar trastuzumab and rituximab on the PBS - information for health professionals and patients
2 January 2019 - New biosimilar brands of trastuzumab (Ontruzant) and rituximab (Truxima) have listed on the PBS on 1 January ...
Posted by Michael Wonder on 20 Dec 2019
Amgen and Allergan submit biologics license application for ABP 798, biosimilar candidate to Rituxan (rituximab), to U.S. FDA
19 December 2019 - Filing for ABP 798 supported by two comparative clinical studies. ...
Posted by Michael Wonder on 18 Dec 2019
Statement from Anna Abram, FDA’s Deputy Commissioner for Policy, Legislation, and International Affairs and Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, on low-cost biosimilar and interchangeable protein products
17 December 2019 - Ensuring an efficient pathway to bring potentially lower-cost biosimilar and interchangeable protein products to market is ...
Posted by Michael Wonder on 13 Dec 2019
Alberta changes coverage of biologic drugs for people with Crohn's, diabetes, arthritis
12 December 2019 - The provincial government says will free up hundreds of millions of dollars in health funding during the ...
Posted by Michael Wonder on 12 Dec 2019
Canadian study shows substantial savings possible with use of biosimilar filgrastim
12 December 2019 - During this week’s annual meeting of American Society of Hematology, researchers from Canada reported that using biosimilar ...
Posted by Michael Wonder on 12 Dec 2019
Alberta will force patients to switch from biologics to cheaper biosimilar medications
12 December 2019 - Alberta will force 26,000 patients on government-sponsored drug plans to switch from expensive drugs that are known ...
Posted by Michael Wonder on 11 Dec 2019
Biosimilar stakeholders praise removal of biologic exclusivity provisions from USMCA
11 December 2019 - An agreement on the United States–Mexico–Canada Agreement, a trade deal that updates the North American Free ...
Posted by Michael Wonder on 06 Dec 2019
FDA approves Amgen's Avsola (infliximab-axxq), for the same indications as Remicade (infliximab)
6 December 2019 - Amgen's fourth FDA approval from biosimilars portfolio. ...
Posted by Michael Wonder on 05 Dec 2019
Is it time to look beyond price with biosimilars?
5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...